Researchers have shown that boosting levels of oestrogen in the brains of mice improved symptoms by slowing the build-up of the toxic protein alpha-synuclein.
The Critical Path for Parkinson's meeting brought together pharmaceutical companies, universities, charities and regulatory bodies to address barriers to new treatments.
We’re investing £100,000 to improve compounds that have the potential to boost the function of brain cell batteries and slow the progression of Parkinson’s.
We’re investing nearly £1 million to find a new treatment that targets energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
In a seminal research paper, published in Lancet Neurology, researchers from King’s College London have used brain scans to uncover early changes in the brain that may happen years before the symptoms of Parkinson's appear.
New research from Harvard University suggests changes to the gut could improve how a common Parkinson’s medication works.